{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:42:12Z","timestamp":1778816532398,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.numecd.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T16:15:31Z","timestamp":1447258531000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Averna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Cefal\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stefanutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2015.11.001_bib1","series-title":"The metabolic basis of inherited disease","first-page":"2863","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.numecd.2015.11.001_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2015.11.001_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2015.11.001_bib4","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2015.11.001_bib5","series-title":"Juxtapid prescribing information","author":"Aegerion Pharmaceuticals Inc.","year":"2013"},{"key":"10.1016\/j.numecd.2015.11.001_bib6","series-title":"Lojuxta summary of product characteristics","author":"Aegerion Pharmaceuticals Inc.","year":"2015"},{"key":"10.1016\/j.numecd.2015.11.001_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2015.11.001_bib8","series-title":"Paper presented at: American Heart Association Scientific Sessions","article-title":"Sustained LDL-C lowering and stable hepatic fat levels in patients with homozygous familial hypercholesterolemia treated with the microsomal transfer protein inhibitor lomitapide: results of an ongoing long-term extension study","author":"Cuchel","year":"2013"},{"key":"10.1016\/j.numecd.2015.11.001_bib9","first-page":"818","article-title":"Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations","volume":"12","author":"Sirtori","year":"1991","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2015.11.001_bib10","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2015.11.001_bib11","series-title":"LDLR database","author":"Leigh","year":"2011"},{"key":"10.1016\/j.numecd.2015.11.001_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jhep.2003.50309","article-title":"Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice","volume":"38","author":"Letteron","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2015.11.001_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1537-2995.2009.02135.x","article-title":"Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis","volume":"49","author":"Stefanutti","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.numecd.2015.11.001_bib14","doi-asserted-by":"crossref","first-page":"314283","DOI":"10.1100\/2012\/314283","article-title":"LDL-apheresis: technical and clinical aspects","volume":"2012","author":"Bambauer","year":"2012","journal-title":"Sci World J"},{"key":"10.1016\/j.numecd.2015.11.001_bib15","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","article-title":"Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia","volume":"64","author":"van Wijk","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2015.11.001_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.numecd.2015.11.001_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","article-title":"Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.numecd.2015.11.001_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2015.11.001_bib19","unstructured":"Aegerion Pharmaceuticals Inc. Data on file."}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475315300533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475315300533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T15:57:24Z","timestamp":1537199844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475315300533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0939475315300533"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2015.11.001","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}